Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Robeson

Internal Medicine Dothan, AL Medical Doctor

NPI 1801861059 CMS profile 217359

1118 Ross Clark Cir, Suite 303, Dothan, AL 36301

Open in the dashboard

General payments

$11,652

774 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Robeson of Dothan, AL is reported in the CMS Open Payments database as having received $11,652 across 774 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,312 72
2024 General $1,927 117
2023 General $1,702 108
2022 General $2,006 139
2021 General $1,995 146
2020 General $1,290 86
2019 General $1,420 106

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Robeson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to James Robeson were reported at $1,312. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year James Robeson Internal Medicine median Middle half National median
2019 $1,420 $159 $48–$570 $163
2020 $1,290 $119 $33–$402 $114
2021 $1,995 $135 $37–$521 $132
2022 $2,006 $141 $42–$496 $149
2023 $1,702 $149 $45–$519 $160
2024 $1,927 $154 $47–$537 $164
2025 $1,312 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $994 84 payments
  2. Novo Nordisk Inc $987 76 payments
  3. GlaxoSmithKline, LLC. $960 62 payments
  4. AstraZeneca Pharmaceuticals LP $886 59 payments
  5. Astellas Pharma US Inc $885 43 payments
  6. Janssen Pharmaceuticals, Inc $747 59 payments
  7. Novartis Pharmaceuticals Corporation $690 52 payments
  8. AbbVie, Inc. $588 35 payments
  9. Merck Sharp & Dohme Corporation $534 42 payments
  10. Pfizer Inc. $509 31 payments
  11. Other $3,873 231 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,635 772 payments
  2. Education $18 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $772 61 payments
  2. XARELTO $712 58 payments
  3. TRELEGY ELLIPTA $692 38 payments
  4. RYBELSUS $676 54 payments
  5. MYRBETRIQ $651 32 payments
  6. FARXIGA $468 31 payments
  7. Repatha $455 37 payments
  8. Kerendia $451 25 payments
  9. BELSOMRA $395 31 payments
  10. EVENITY $393 36 payments
  11. Other $10,481 715 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 170 drugs

Part D claims

11,409

Median for Internal Medicine: 777

Drug cost

$1,083,210

Median for Internal Medicine: $73,373

Branded share of claims

20.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 157 $184,315
Farxiga Dapagliflozin Propanediol Brand 102 $107,319
Mounjaro Tirzepatide Brand 55 $86,675
Jardiance Empagliflozin Brand 61 $79,505
Ozempic Semaglutide Brand 50 $74,961
Xarelto Rivaroxaban Brand 51 $54,520
Trulicity Dulaglutide Brand 38 $41,991
Januvia Sitagliptin Phosphate Brand 28 $32,352
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $32,350
Rybelsus Semaglutide Brand 17 $29,014

The 10 drugs with the highest cost, of 170 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 121 billing codes

Paid by Medicare

$331,008

Of which drugs: $72,955

Medicare patients

1,157

Average age 76

Services billed

19,328

620 women, 537 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 40%
Ischemic heart disease 39%
Chronic kidney disease 38%
Atrial fibrillation 32%
Depression 28%
Heart failure 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 36 2,102 $41,118
Vaccine for influenza for injection into muscle 90662 Office 124 126 $9,244
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 15 15 $423
Injection, methylprednisolone acetate, 1 mg J1010 Office 29 2,166 $195
Injection, methylprednisolone acetate, 80 mg J1040 Office 19 19 $100
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 42 $40
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 48 273 $21

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$179 — —
TRELEGY ELLIPTA
$153 34 —
Veozah
$149 — —
QULIPTA
$126 — —
Repatha
$91 22 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

774 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record